N. Leigh Anderson, Norman G. Anderson, Terry W. Pearson, Christoph H. Borchers, Amanda G. Paulovich, Scott D. Patterson, Michael Gillette, Ruedi Aebersold, and Steven A. Carr
The lack of sensitive, specific, multiplexable assays for most human proteins is the major barrier impeding development of candidate biomarkers into clinically useful tests. Recent progress in mass spectrometry-based assays for proteotypic peptides, particularly those with specific affinity peptide enrichment, offers a systematic and economical path to comprehensive quantitative coverage of the human proteome. A compete suite of assays, e.g., two peptides from the protein product of each of the ~20,500 human genes (here termed the hPDQ project), would enable rapid and systematic verification of candidate biomarkers, and lay a quantitative foundation for subsequent efforts to define the larger universe of splice variants, post-translational modifications, protein-protein interactions and tissue localization.
Read full paper in press at MCP Online
Comments welcome.
2 responses so far ↓
Leigh Anderson // January 27, 2009 at 12:48 PM
Strange to comment on an editorial with my name on it, but it seems someone has to start the blog to get the machinery working. Given the change in administration in US, the environment for focused biology projects is better than it has been for some time, particularly where there is a plausible impact on healthcare. Time for a vigorous discussion….
Scott Monsma // March 6, 2009 at 10:10 PM
As I understand, your paper is a proposal- have you seen much interest yet from commercial entities?